In our experiments, we noted that co-treatment of prostate cancer cells with vitamin B5 and CDK9 inhibitor induces combinatorial antiproliferative effects and further increased DNA damage, which were associated with decreased OGT expression (Fig. 4). This evidence concerns the gene CDK9 and prostate cancer.